Summary & Overview
CPT 0490T: Autologous Adipose-Derived Cell Injection for Hand Scleroderma
CPT code 0490T identifies an autologous adipose-derived cell therapy workflow: harvesting a patient’s fat, processing to achieve a specific concentration/dilution of regenerative cells, and injecting the processed material into the hands to treat scleroderma. The code is notable as a targeted regenerative procedure addressing localized fibrotic changes in the hands, with implications for clinical practice patterns, coverage policies, and coding consistency nationwide.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for using 0490T, the typical sites of service where the procedure is performed, common modifiers used with procedural reporting, and national payer coverage considerations. The report also outlines benchmarks and policy updates relevant to adoption and billing of this regenerative therapy, and highlights documentation elements and service-line implications for surgical, ambulatory, and outpatient settings.
This summary is intended for a national audience of clinicians, billing professionals, and policy analysts seeking a clear, practical briefing on the clinical role and payer landscape for CPT code 0490T without state-specific detail.
Billing Code Overview
CPT code 0490T describes a procedure in which the provider harvests the patient’s own fat cells, subjects them to processing that yields a specific concentration and dilution of regenerative cells, and returns the processed material to the patient for treatment of scleroderma in the hands. The procedure is reported for multiple injections in one or both hands.
-
Service type: Autologous adipose-derived regenerative cell harvest, processing, and injection for localized hand scleroderma
-
Typical site of service: Ambulatory surgical center or hospital outpatient setting; portions of the procedure (harvest and injections) may also occur in physician office procedure suites depending on facility capabilities and local practice patterns
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with systemic sclerosis (scleroderma) experiencing progressive digital fibrosis, pain, stiffness, reduced range of motion, and impaired hand function. The treating provider (often a plastic surgeon, hand surgeon, or rheumatologist working with procedural specialists) performs ambulatory lipoharvest of the patient’s subcutaneous adipose tissue under local or monitored anesthesia care. The harvested adipose tissue is processed in a closed or laboratory system to concentrate regenerative cells and remove excess fluid, then multiple injections of the processed autologous cell/fat suspension are delivered into both hands (subcutaneous and periarticular tissues of the digits) to address skin tightness and microvascular and soft-tissue changes. Typical workflow: preprocedure evaluation and informed consent, sterile lipoharvest (abdomen or thigh), processing/centrifugation or filtration, multiple hand injections (often bilateral, multiple digits), brief postprocedure observation in an outpatient surgical center or office procedure room, and discharge with wound and activity instructions. Typical site of service: outpatient ambulatory surgery center or office-based procedure room with appropriate sterile and monitoring capabilities. Typical payors involved include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for coverage adjudication and medical necessity review.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |